Medium

Step 1: The overall sentiment of the management's discussion appears to be cautious and realistic. They make forward-looking statements but also acknowledge substantial risks and uncertainties.
Quote: "This report and other written or oral statements that the Company makes from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties."

Step 2: The company took on significant debt in June 2020 for the Upjohn Debt Transactions, and they entered into various financing arrangements. They also mention making a cash payment of $12 billion to Pfizer.
Quote: "In June 2020, in connection with the Transaction, the Company (i) incurred $11.4 billion of debt in the Upjohn Debt Transactions..."

Step 3: The company's upcoming transaction with Mylan seems to be progressing as planned, with all required antitrust clearances obtained. The close of the Transaction is expected to be on November 16, 2020, subject to customary closing conditions.
Quote: "In October 2020, Pfizer announced that it had set the close of business on November 13, 2020 as the record date for the proposed spin-off and that the Transaction is expected to close on November 16, 2020..."

Step 4: Considering the cautious sentiment, the significant debt incurred, and the progress of the Transaction with Mylan, the company faces a medium risk of bankruptcy. While the transaction could bring benefits, the debt burden and uncertainties mentioned make the future outlook uncertain.
Therefore, based on the management's discussion in the filing, the company has a medium risk of bankruptcy.